Celiac Disease - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 83
Inquire Before Buying

Celiac Disease - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 6 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Celiac Disease - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
Amgen Inc
Calypso Biotech SA
F. Hoffmann-La Roche Ltd
Glenmark Pharmaceuticals Ltd
ImmusanT Inc
Innovate Biopharmaceuticals Inc
Intrexon Corp
Selecta Biosciences Inc
Takeda Pharmaceutical Company Ltd
Topas Therapeutics GmbH
Zedira GmbH
Celiac Disease - Drug Profiles
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVX-176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBR-830 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kuma-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Tropical Spastic Paraparesis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzymes to Inhibit Gluten for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7625 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Product Development Milestones
Featured News & Press Releases
Aug 29, 2017: ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science
Jun 06, 2017: Innovate Biopharmaceuticals to present progress towards phase 3 celiac disease trials at BIO 2017 Convention
May 12, 2017: ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients
May 08, 2017: ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach
May 02, 2017: ImmunogenX to Make Highlighted Presentations at DDW 2017
Feb 22, 2017: ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2 for the Treatment of Celiac Disease
Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Celiac Disease Treatment
Jan 04, 2017: Innovate Biopharmaceuticals Provides Update on larazotide acetate (INN-202)
Nov 30, 2016: Zedira receives funding from the German Government for the development of transglutaminase inhibitor ZED-1227 for the treatment of diabetic nephropathy
Jul 01, 2016: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease
May 19, 2016: ImmusanT Announces Presentations at Digestive Disease Week 2016
May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease
Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II
Oct 20, 2015: Additional subsidy funding for clinical development of a celiac disease drug
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Celiac Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Celiac Disease - Pipeline by Amgen Inc, H2 2017
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2017
Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
Celiac Disease - Pipeline by ImmusanT Inc, H2 2017
Celiac Disease - Pipeline by Innovate Biopharmaceuticals Inc, H2 2017
Celiac Disease - Pipeline by Intrexon Corp, H2 2017
Celiac Disease - Pipeline by Selecta Biosciences Inc, H2 2017
Celiac Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2017
Celiac Disease - Pipeline by Zedira GmbH, H2 2017
Celiac Disease - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Celiac Disease, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017
  • Diarrhea - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 2000 Onwards        Pages: 154
    Diarrhea - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Pipeline Review, H1 2018, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape. Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms inc......
  • Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 2000 Onwards        Pages: 79
    Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H1 2018, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) (Gastrointestinal) pipeline landscape. When the liquid content of the stomach refluxes into the oesophagus, that condition ......
  • Colitis - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 2000 Onwards        Pages: 93
    Colitis - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2018, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammat......
  • Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2018
    Published: 18-Jan-2018        Price: US 2000 Onwards        Pages: 34
    Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2018, provides an overview of the Functional (Non Ulcer) Dyspepsia (Gastrointestinal) pipeline landscape. Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called ......
  • United States Lansoprazole Market Report 2018
    Published: 17-Jan-2018        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Lansoprazole market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Lan......
  • Global Esomeprazole Market Research Report 2018
    Published: 17-Jan-2018        Price: US 2900 Onwards        Pages: 116
    In this report, the global Esomeprazole market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Esomeprazole in these regions, from 2013 to 2025 (forecast), covering - North America - Europe - China - Japan......
  • Global Irritable Bowel Syndrome (IBS) Market Research Report 2018
    Published: 12-Jan-2018        Price: US 3500 Onwards        Pages: 131
    Summary Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimate......
  • Global Gastrointestinal Drugs Market Size, Status and Forecast 2025
    Published: 10-Jan-2018        Price: US 3300 Onwards        Pages: 92
    This report studies the global Gastrointestinal Drugs market, analyzes and researches the Gastrointestinal Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Abbott Laboratories - Allergan - AstraZeneca - Bayer - Boehringer Ingelheim - GlaxoSmithKline - Janssen Biotech - Sanofi - Takeda Pharmaceutical - Valeant Phar......
  • Global Anti Peptic Ulcer Drugs Market Size, Status and Forecast 2025
    Published: 10-Jan-2018        Price: US 3300 Onwards        Pages: 104
    This report studies the global Anti Peptic Ulcer Drugs market, analyzes and researches the Anti Peptic Ulcer Drugs development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Eisai - Daewoong Pharmaceutical - Takeda Pharmaceutical - HeliCure - AstraZeneca - Ore Pharmaceuticals - Sihuan Pharmaceutical - GlaxoSmithKline - Pfizer - A......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs